

PTO 892 DEAFCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  NOTICE OF REFERENCES CITED	SERIAL NUMBER  09/599,877	Art Unit  1648	Attachment to Paper Number
			7

APPLICANTS : Lennerstrand, J. and B. Larder
---

U.S. PATENT DOCUMENTS
-----------------------

*		DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS
--------------------------

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	PERTINENT DRW SPEC

*		OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
---	--	---

1	*	Ekstrand, D. H. L., <i>et al.</i> , 1996, "A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation", <i>Biotechnol. Appl. Biochem.</i> 23:95-105.
2	*	Meyer, P. R., <i>et al.</i> , 1999, "A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase", <i>Mol. Cell</i> 4:35-43.
3	*	Arion, D., <i>et al.</i> , 1998, "Phenotypic mechanism of HIV-1 resistance to 3'-Azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase", <i>Biochem.</i> 37:15908-15917.
4	*	Ueno, T., <i>et al.</i> , 1995, "Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates", <i>J. Biol. Chem.</i> 270(4):23605-23611.
a	5	Larder, B. A. and D. K. Stammers, 1999, "Closing in on HIV drug resistance", <i>Nature Struct. Biol.</i> 6(2):103-106.
b	*	Larder, B. A., <i>et al.</i> , 1999, "A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance", <i>Antimicrob. Agents Chemother.</i> 43(8):1961-1967.

EXAMINER  Jeffrey S. Parkin, Ph.D.	DATE  01/10/02	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).  PAGE 1 OF 1
--	----------------------	---